Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Get Free Report) saw a large increase in short interest during the month of June. As of June 15th, there was short interest totalling 229,400 shares, an increase of 17.6% from the May 31st total of 195,100 shares. Currently, 4.1% of the company’s shares are short sold. Based on an average trading volume of 33,700 shares, the days-to-cover ratio is currently 6.8 days.
Analysts Set New Price Targets
Separately, HC Wainwright reiterated a “buy” rating and issued a $36.00 price objective on shares of Greenwich LifeSciences in a research report on Wednesday, May 22nd.
Check Out Our Latest Report on GLSI
Greenwich LifeSciences Stock Performance
Greenwich LifeSciences (NASDAQ:GLSI – Get Free Report) last issued its quarterly earnings data on Monday, May 20th. The company reported ($0.19) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.20) by $0.01. Equities research analysts predict that Greenwich LifeSciences will post -0.75 EPS for the current fiscal year.
Insider Activity
In related news, CEO Snehal Patel purchased 174,825 shares of the stock in a transaction dated Thursday, June 13th. The stock was bought at an average cost of $14.30 per share, with a total value of $2,499,997.50. Following the purchase, the chief executive officer now directly owns 5,525,602 shares in the company, valued at approximately $79,016,108.60. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. 52.86% of the stock is currently owned by company insiders.
Hedge Funds Weigh In On Greenwich LifeSciences
A hedge fund recently raised its stake in Greenwich LifeSciences stock. Vanguard Group Inc. grew its position in shares of Greenwich LifeSciences, Inc. (NASDAQ:GLSI – Free Report) by 0.6% in the first quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 223,102 shares of the company’s stock after acquiring an additional 1,420 shares during the quarter. Vanguard Group Inc. owned 1.73% of Greenwich LifeSciences worth $4,449,000 at the end of the most recent reporting period. 4.16% of the stock is owned by hedge funds and other institutional investors.
About Greenwich LifeSciences
Greenwich LifeSciences, Inc, a clinical-stage biopharmaceutical company, focuses on the development of novel cancer immunotherapies for breast cancer and other HER2/neu-expressing cancers. Its lead product candidate is the GP2, an immunotherapy, which is in Phase III clinical trial to prevent breast cancer recurrences in patients who have previously undergone surgery.
Recommended Stories
- Five stocks we like better than Greenwich LifeSciences
- With Risk Tolerance, One Size Does Not Fit All
- What’s Behind Walgreens Stock Plunge: What Investors Can Do Next
- What is a Death Cross in Stocks?
- MarketBeat Week in Review – 6/24 – 6/28
- Best Stocks Under $10.00
- General Mills Stock Drops After Revenue Miss in Fiscal Q4 2024
Receive News & Ratings for Greenwich LifeSciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Greenwich LifeSciences and related companies with MarketBeat.com's FREE daily email newsletter.